About SIGA Technologies (OTCMKTS:SIGA)
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company's lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$14.99 million
Price / Sales25.53
Cash Flow$0.51 per share
Price / Cash9.57
Book Value($3.65) per share
Price / Book-1.33
Return on EquityN/A
Return on Assets-23.22%
SIGA Technologies (OTCMKTS:SIGA) Frequently Asked Questions
What is SIGA Technologies' stock symbol?
SIGA Technologies trades on the OTCMKTS under the ticker symbol "SIGA."
How were SIGA Technologies' earnings last quarter?
SIGA Technologies, Inc. (OTCMKTS:SIGA) posted its quarterly earnings data on Thursday, May, 1st. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.28. The biotechnology company had revenue of $0.55 million for the quarter, compared to analysts' expectations of $26.50 million. View SIGA Technologies' Earnings History.
When will SIGA Technologies make its next earnings announcement?
Who are some of SIGA Technologies' key competitors?
Some companies that are related to SIGA Technologies include Theratechnologies (TH), Mirati Therapeutics (MRTX), OrganiGram (OGI), VBI Vaccines (VBIV), XOMA (XOMA), Osiris Therapeutics (OSIR), Anavex Life Sciences (AVXL), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect (CFRX), Concordia International (CXR), Sevion Therapeutics (SVON), Soligenix (SNGX), Windtree Therapeutics (WINT), Mateon Therapeutics (MATN), Tetralogic Pharmaceuticals (TLOG), Affymax (AFFY) and Cubist Pharmaceuticals (CBST).
Who are SIGA Technologies' key executives?
SIGA Technologies' management team includes the folowing people:
- Eric A. Rose M.D., Executive Chairman of the Board (Age 66)
- Phillip Louis Gomez III, Chief Executive Officer, Director (Age 49)
- Daniel J. Luckshire, Chief Financial Officer, Executive Vice President, Secretary (Age 44)
- Dennis E. Hruby Ph.D., Chief Scientific Officer, Vice President (Age 63)
- James J. Antal CPA, Independent Director (Age 65)
- Michael Jonathan Bayer, Independent Director (Age 66)
- Thomas E. Constance, Independent Director (Age 81)
- Jeffrey B Kindler, Independent Director (Age 61)
- Joseph W. Marshall III, Independent Director (Age 64)
Who owns SIGA Technologies stock?
How do I buy SIGA Technologies stock?
Shares of SIGA Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SIGA Technologies' stock price today?
One share of SIGA Technologies stock can currently be purchased for approximately $4.85.
How big of a company is SIGA Technologies?
SIGA Technologies has a market capitalization of $382.71 million and generates $14.99 million in revenue each year. The biotechnology company earns $-39,690,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. SIGA Technologies employs 36 workers across the globe.
How can I contact SIGA Technologies?
SIGA Technologies' mailing address is 27 EAST 62ND STREET, NEW YORK NY, 10065. The biotechnology company can be reached via phone at 212-672-9100 or via email at [email protected]
MarketBeat Community Rating for SIGA Technologies (SIGA)MarketBeat's community ratings are surveys of what our community members think about SIGA Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
SIGA Technologies (OTCMKTS:SIGA) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
SIGA Technologies (OTCMKTS:SIGA) Earnings History and Estimates Chart
SIGA Technologies (OTCMKTS SIGA) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/13/2017|| || || || || || || || |
|5/1/2014||Q1||$0.22||($0.06)||$26.50 million||$0.55 million||View||Listen|
|3/10/2014||Q413||($0.08)||$2.50 million||$0.90 million||View||N/A|
|3/6/2013||Q4 2012||($0.07)||($0.06)||$5.00 million||$2.50 million||View||N/A|
|11/5/2012||Q312||$0.11||($0.06)||$3.60 million||$2.30 million||View||N/A|
SIGA Technologies (OTCMKTS:SIGA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for SIGA Technologies (OTCMKTS:SIGA)
No dividend announcements for this company have been tracked by MarketBeat.com
SIGA Technologies (OTCMKTS SIGA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.71%
Institutional Ownership Percentage: 6.69%
SIGA Technologies (OTCMKTS SIGA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/7/2014||& Forbes Holdings I Macandrews||Director||Buy||199,727||$1.50||$299,590.50|| |
|9/26/2014||Bruce Slovin||Director||Sell||25,000||$1.35||$33,750.00|| |
|9/24/2014||& Forbes Holdings I Macandrews||Director||Buy||204,157||$1.34||$273,570.38|| |
|9/23/2014||& Forbes Holdings I Macandrews||Director||Buy||151,158||$1.33||$201,040.14|| |
|9/17/2013||Michael Bayer||Director||Buy||15,000||$3.58||$53,700.00|| |
|9/13/2013||Michael Bayer||Director||Sell||15,000||$3.55||$53,250.00|| |
|5/30/2013||Bruce Slovin||Director||Sell||15,000||$3.83||$57,450.00|| |
|5/24/2013||Joseph W Marshall III||Director||Buy||7,000||$3.59||$25,130.00|| |
SIGA Technologies (OTCMKTS SIGA) News Headlines
SIGA Technologies (OTCMKTS:SIGA) SEC Filings
|ESOPUS CREEK VALUE SERIES FUND LP - SERIES A (Filed by)|
SIGA Technologies (Subject)
|Form SC 13G|
SIGA Technologies (OTCMKTS:SIGA) Income Statement, Balance Sheet and Cash Flow Statement
SIGA Technologies (OTCMKTS SIGA) Stock Chart for Monday, December, 11, 2017